Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.

After rising by 137% in one day upon the publication of favorable phase 2 clinical trial results on Feb. 27, Viking Therapeutics (VKTX 10.60%) is now doubtlessly on many investors' radars. Soon enough, the biotech will likely try to launch a new weight loss medication capable of rivaling Novo Nordisk's (NVO 3.72%) blockbuster obesity drug, Wegovy. That means people who feel that they learned about Novo Nordisk's rapidly growing obesity care segment too late to see any upside from an investment now have anot ...